News

USPSTF 'insufficient evidence' stance repeats 2014 recommendation

Treatment is first non-statin LDL-C lowering treatment approved in years.

Eisai disagrees with FDA decision.

News about UnitedHealth, Alkermes, M4A, and MA that you need to know about. 

When it comes to solving your revenue cycle management challenges, your solutions are closer than they appear.

The collaboration will open new opportunities in the care experience by enabling healthcare organizations to automate the delivery of dynamically rendered, personalized and time-sensitive digital content across the clinical and operational aspects of a patient’s care journey.

Scheduled to face off on February 27. 

Princeton healthcare historian sees lowering age of Medicare eligibility as doable.

Weekly news from the healthcare C-Suite.

Trade group had previously documented even slower coverage by Part D plans.

Three takeaways from Stat's interview with the Senate Finance Committee chairman.

A wave of new business is attempting to shake up, improve primary care.

Two studies in JAMA produce meh results for polygenic risk scores

Treatments include meds for arthritis pain and allergy eye drops.

Treatment will be first to target a specific type of advanced lung cancer.

V-Sensor- and e-Checkup-enabled smartphones measure temperature, blood pressure, respiration and other vital signs to medical accuracy.

Michael Bloomberg wants a Medicare-like public insurance option, not Medicare for all. It's what you'd expect from a candidate who is appealing for support from moderate Democrats.

2020 wellness survey finds employees want more health programs, but few employers are offering them.

Health professionals are sharing what healthcare is becoming and what they believe it will become in the future.

As number of procedures has decreased, patient profile has shifted.

Trump administration hints that it may agree and is considering a broader scope of practice for nurse practitioners and physicians.

Data security is just one part of it. Payers also need to deliver an excellent member experience to create and maintain trust.

Twenty percent of seven in-network elective surgeries for a large national insurer resulted in a “surprise” out-of-network bill; averaging at $2,011.

FDA cleared the first generic sodium iodide product to treat hyperthyroidism and carcinoma of the thyroid.

Here’s a look at what payers and providers can expect to occur, why each change is occurring, and how payers and providers can prepare for each change.

FDA's Center for Drug Evaluation and Research approved fewer new treatments in 2019.

Top thought leaders share their favorite non-business reads.